About AVT
Browse Articles
Customer Services


Correction: Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study

Benoît Trottier, Jordan E Lake, Ken Logue, Cynthia Brinson, Lizette Santiago, Clare Brennan, Justin A Koteff, Brian Wynne, Judy Hopking, Catherine Granier, Michael Aboud

Corresponding author name: Justin A Koteff
Corresponding author e-mail: justin.a.koteff@viivhealthcare.com

Citation: Antiviral Therapy 2017; 22:459-460
doi: 10.3851/IMP3192

Date accepted: 12 September 2017
Date published online: 13 September 2017


No abstract included.


Copyright © 2021 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.